在儿科刺激性肠综合征中Bifidobacterium adolescentis PRL2019:一个多中心,随机,双盲,安慰剂控制的试验
Valentina Giorgio1, Giovanna Quatrale2,3, Maurizio Mennini2,3
1Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Catholic University of Sacred Heart, 00168 Rome, Italy.
Microorganisms
|March 27, 2025
概括
Bifidobacterium adolescentis PRL2019显著改善了儿童的刺激性肠综合征 (IBS) 症状. 这种益生菌降低了症状严重程度,并对肠道习惯产生了积极影响,特别是在IBS-便秘患者中.
科学领域:
- 胃肠道学和微生物学
- 儿科健康 儿科健康
- 免疫学 免疫学 免疫学
背景情况:
- 肠道微生物群的改变与胃肠道炎症和刺激性肠道综合征 (IBS) 的发生有关.
- 青少年的Bifidobacterium产生胺黄油酸 (GABA),一个神经递质在IBS患者减少.
- 在IBS患者的GABA水平降低可能导致肠道功能异常和症状.
研究的目的:
- 为了评估Bifidobacterium adolescentis PRL2019在治疗儿童IBS中的疗效.
- 评估这种益生菌对IBS症状严重程度和肠道习惯的影响.
主要方法:
- 一个多中心,随机,双盲,安慰剂对照试验,涉及72名被诊断患有IBS的儿童.
- 参与者每天接受Bifidobacterium adolescentis PRL2019 (20 × 10 ^ 9 CFU) 或安慰剂,持续12周.
- 症状评估使用了验证的得分 (IBS SSS,PIS,PFS,LIS) 和每周评估的布里斯托尔便图 (BSC).
主要成果:
- 在Bifidobacterium adolescentis PRL2019组中,显著更高比例的患者实现了完全缓解 (52.8%对19.4%).
- 与安慰剂相比,益生菌组在IBS-SSS,PIS,LIS和PFS中显示出显著的改善.
- Bifidobacterium adolescentis PRL2019对肠道习惯产生了积极的影响,增加了正常的便 (BSC类型3-4),特别是在IBS-便秘亚型中.
结论:
- Bifidobacterium adolescentis PRL2019有效地减少了儿科IBS的症状严重程度和频率.
- 益生菌对肠道习惯产生积极影响,特别是对于患有IBS-便秘的儿童.
- 这项研究支持使用Bifidobacterium adolescentis PRL2019作为儿童IBS的治疗选择.
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Drugs for Treatment of Constipation-Predominant IBS
1.1K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS
836
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
836
Irritable Bowel Syndrome I: Introduction
1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Inflammatory Bowel Disease IV: Pharmacological Management
895
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
895
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1000
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1000


